The EPS projection of PTC Therapeutics, Inc. (NASDAQ:PTCT) for quarter ended 2016-09-30 is $-1.13. Last week, the projection for EPS was $-1.13 against target of $-1.13, a month earlier. While 2-months ago, this projection was $-1.13 versus forecast of $-1.13a quarter months earlier, posting a deviation of 0%.
PTC Therapeutics, Inc. (NASDAQ:PTCT) posted that 18 days earlier, the share price was revised 0 times on upside. In addition, negative revisions were 0.
In last week, negative EPS revisions were 0 times and positive EPS revisions were 0 times. In last one-month and two month the positive revisions were 0 and 0. While in last 120 and 90 days, positive revisions were 1, and 1, correspondingly.
The per-share earnings downgrade for PTC Therapeutics, Inc. (NASDAQ:PTCT) in the preceding 30 and 120 were 1 and 2. While in 60 and 90 days were 1, and 2, in that order.
PTC Therapeutics, Inc. (NASDAQ:PTCT) EPS target was $-1.13 for the quarter closed 1. It was based on 6 calls. As on 2016-05-05 the EPS was $-1.16. The change was $0.05, posting a deviation of 4.13%. The price projections gave a standard deviation of 0.24.
Quarterly Sales Estimates
PTC Therapeutics, Inc. (NASDAQ:PTCT) sales prediction for the fiscal 2016 stands at $20.8 and the median estimate is at $20.8. Almost 2 analysts gave sales target.
Among this, the highest sales estimate is $21.901 while the lowest target is $19.7 showing standard deviation of 1.556%.
As many as 2 analysts have positive sales targets revision while 2 reduced sales estimates, posting a deviation of -7.543%.
Last month, 2 experts have positive sales number revision. Also, 2 research groups lowered the sales projections, posting a deviation of -8.086%.
A quarter ago, 2 hiked sales target and 2 reduced sales forecast, posting a deviation of -11.338%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...